drugset / Trial / NCT03421197
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of PPC-06 (tepilamide fumarate) extended release in subjects with moderate-to-severe plaque psoriasis.
Timeline
- Start
- 2018-01-25
- Primary completion
- 2020-03-30
- Completion
- 2020-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tepilamide Fumarate | Small molecule | 400 mg | — |
| Subject | Tepilamide Fumarate | Small molecule | 600 mg | — |